84% of patients surveyed
want to be educated by you1

Take action—
Prescribe ARESTIN® (minocycline HCl) Microspheres, 1 mg

View our Patient Communication Tools

REFERENCE: 1. Data on file. OraPharma, Inc. Horsham, PA; 2011.

~50% of adult Americans
over 30 have periodontal disease1,2

Take action—
Prescribe ARESTIN® (minocycline HCl) Microspheres, 1 mg

REFERENCES: 1. Eke P, Dye B. Assessment of self-report measures for
predicting population prevalence of periodontitis. J Periodontol.
2009;80:1371-1379. 2. Albandar J, Kingman A. Gingival recession,
gingival bleeding, and dental calculus in adults 30 years of age and
older in the United States. J Periodontol. 1999;70:30-43.

87% of patients said it was
important that you take appropriate
action to fight the infection1

Take action—
Prescribe ARESTIN® (minocycline HCl) Microspheres, 1 mg

View our Patient Communication Tools

REFERENCE: 1. Data on file. OraPharma, Inc. Horsham, PA; 2011.

What Do You Think?

Patient Education

Download and print educational pieces to use in your office to help your patients understand periodontitis and the importance of your treatment plan.

Help them with the useful tools in the Patient Communication section.

ARESTIN® Rx Access

Learn how you may be able to help your patients access their medical insurance prescription benefits to pay for ARESTIN®.

Watch our latest Webinar: ARESTIN® Rx Access: How to Put Patients' Rx Health Benefits to Use.

While ARESTIN® has been demonstrated along with SRP to reduce pocket depth and bacteria in patients with periodontal disease, it has not been proven in clinical trials to reduce tooth loss.

INDICATION

ARESTIN® is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION

ARESTIN® should not be used in any patient who has a known sensitivity to minocycline or tetracyclines. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth, and therefore should not be used in children or in pregnant or nursing women. Hypersensitivity reactions that included, but were not limited to, anaphylaxis, angioneurotic edema, urticaria, rash, swelling of the face and pruritus have been reported with the use of ARESTIN®. In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome and pain.

Please see Full Prescribing Information

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Contact us with questions about your account or MyArestin.com®